{"messages": [{"role": "system", "content": "You are a clinical protocol document generator, given a synopsis you are tasked to construct the objectives and endpoints section for a clinicial trial protocol document"}, {"role": "user", "content": "[Title: Efficacy and safety of EGT0001442 compared with placebo in patients with type 2 diabetes mellitus inadequately controlled by diet and exercise and up to one oral anti-diabetes agent., Study Description: A multinational, 2-arm parallel groups, randomized, double-blind placebo-controlled study to compare the treatment of once daily EGT0001442 at 30 mg with matching placebo in treatment-naïve type 2 diabetic patients or with diet and exercise in combination with one oral antidiabetes drug and an HbA1c of 7-10%. Approximately 300 eligible subjects will start a 2-week placebo run-in period prior to being randomly assigned to either once daily EGT0001442 or placebo in a 1:1 ratio for 24 weeks. At week 24, subjects who have completed the main treatment period will continue to receive the study drug until week 96., Objectives: Primary Objective: To assess the efficacy of EGT0001442 in lowering HbA1c at week 24 compared with placebo. Secondary Objectives: To assess the efficacy of EGT0001442 in lowering FPG at weeks 2 and 24 compared with placebo. To assess the efficacy of EGT0001442 based on the proportion of subjects in the EGT0001442 group reaching the ADA target HbA1c of <7% compared with placebo. To assess the effect of EGT0001442 on systolic and diastolic blood pressure compared with placebo. To assess the effect of EGT0001442 on body weight compared with placebo. To assess the change in HbA1c over time, week 1 to week 96. To assess the safety of EGT0001442 in patients with T2DM., Endpoints: Primary Endpoint: Change in HbA1c from baseline to week 24. Secondary Endpoints include change in fasting plasma glucose (FPG), proportion of subjects achieving target HbA1c, changes in body weight, blood pressure, and safety evaluations., Study Population: Approximately 300 patients inadequately controlled by diet and exercise or treatment with a single oral anti-diabetes agent, aged ≥18 years, diagnosed with type 2 diabetes, and with HbA1c between 7% and 10%., Phase: 3, Description of Sites/Facilities Enrolling Participants: Study to be conducted at multiple investigative sites in three countries with competitive enrollment capped at 30% of total subjects from any single site., Description of Study Intervention: EGT0001442 tablets (30 mg once daily by mouth)., Study Duration: Approximately 102 weeks, including 2-week placebo run-in, 24-week primary evaluation, and 72-week extension., Participant Duration: Each participant is involved for a maximum of 102 weeks, including screening, treatment, and follow-up.]"}, {"role": "assistant", "content": "[[Primary Objectives: The primary objective of this study is to assess the efficacy of EGT0001442 in lowering HbA1c at week 24 compared with placebo., Corresponding Endpoints: The primary endpoint is the change in HbA1c from baseline to week 24. HbA1c will be assessed at multiple points, and the last HbA1c value prior to any rescue medication will be carried forward for analysis., ], [Secondary Objectives: The secondary objectives are to assess the efficacy of EGT0001442 in lowering fasting plasma glucose (FPG) at weeks 2 and 24 compared with placebo; the proportion of subjects achieving the American Diabetes Association (ADA) target HbA1c of <7% compared with placebo; changes in systolic and diastolic blood pressure; body weight differences; the longitudinal change in HbA1c from week 1 to week 96; and the safety profile of EGT0001442 in patients with T2DM., Corresponding Endpoints: Secondary endpoints include changes in FPG, blood pressure, body weight, and HbA1c measured over time. These will be assessed using paired t-tests and linear mixed models. Adverse events and safety data will also be recorded and analyzed., ],[Tertiary/Exploratory Objectives: None explicitly mentioned in the document or associated sections., Corresponding Endpoints: None explicitly mentioned in the document or associated sections., ]]"}]}
{"messages": [{"role": "system", "content": "You are a clinical protocol document generator, given a synopsis you are tasked to construct the objectives and endpoints section for a clinicial trial protocol document"}, {"role": "user", "content": "[Title: Safety and Efficacy of Imatinib for Preserving Beta-cell Function in New-onset Type 1 Diabetes Mellitus, Study Description: The study is a multicenter, two-arm, double-blind, placebo-controlled, phase II clinical trial. Participants are randomly assigned 2:1 to receive either imatinib (400 mg/day for adults or 260 mg/m²/day for children) or a placebo for 26 weeks. Both groups undergo identical procedures and are followed for 104 weeks. The primary endpoint is the 2-hour C-peptide AUC from a mixed-meal tolerance test (MMTT) measured at 52 weeks. Secondary endpoints include various measures of efficacy, safety, and metabolic outcomes, Objectives: Primary objective is to determine whether imatinib slows autoimmune ß-cell destruction, preserving C-peptide secretion in Type 1 Diabetes Mellitus (T1DM). Secondary objectives include assessing prolonged clinical efficacy, safety in terms of hepatic, bone marrow, cardiac, and cutaneous toxicity, and the drug's mechanistic effects on insulin sensitivity and immune responses, Endpoints: Primary Endpoint: MMTT-stimulated 2-hour C-peptide AUC at week 52. Secondary Endpoints: Peak and 4-hour C-peptide AUC at weeks 52 and 104, insulin use, hypoglycemic events, HbA1C levels, and mechanistic and metabolic assessments, Study Population: Participants aged 12-45 with recent-onset T1DM (diagnosed within 100 days), meeting ADA criteria, and positive for at least one islet cell autoantibody, Phase: Phase II, Description of Sites/Facilities Enrolling Participants: Multicenter study conducted at sites with necessary facilities and expertise for monitoring and managing participants with T1DM, Description of Study Intervention: Participants receive either imatinib or a placebo daily for 26 weeks, followed by identical intensive diabetes management for 104 weeks. Mechanistic and safety assessments are conducted throughout the study duration, Study Duration: Total study duration is 4 years. Recruitment takes 18-24 months, with each participant followed for 104 weeks, Participant Duration: Each participant's involvement lasts for 104 weeks.]"}, {"role": "assistant", "content": "[[Primary Objectives: Determine whether imatinib will slow the progression of the autoimmune destruction of ß cells and lead to the preservation of C-peptide secretion in T1DM., Corresponding Endpoints: The primary endpoint is an MMTT-stimulated 2-hour C-peptide AUC at week 52.], [Secondary Objectives: Assess whether the drug has prolonged clinical efficacy, assess the effect of imatinib on selected secondary clinical outcomes, and determine the safety of imatinib in participants with T1DM, especially with respect to hepatic, bone marrow, cardiac, and cutaneous toxicity. Mechanistic studies include characterizing how imatinib alters general and diabetes-specific immune responses and assessing effects on insulin sensitivity., Corresponding Endpoints: Secondary endpoints include MMTT-stimulated peak and 4-hour C-peptide AUC at weeks 52 and 104, HbA1c levels at weeks 52 and 104, insulin use in units/kg at weeks 52 and 104, and rates of adverse events related to safety. Additional metabolic and mechanistic endpoints include effects on insulin resistance and immune tolerance], [Tertiary/Exploratory Objectives: Exploratory endpoints focus on mechanistic and metabolic aspects such as immunological assessments and effects on insulin resistance, assessed through adiponectin, proinsulin levels, and proinsulin/C-peptide ratio., Corresponding Endpoints: Immunological assessments related to immune tolerance and metabolic assessments such as the proportion of patients who are exogenous insulin-free at weeks 52 and 104 with HbA1C ≤ 6.5%]]"}]}
{"messages": [{"role": "system", "content": "You are a clinical protocol document generator, given a synopsis you are tasked to construct the objectives and endpoints section for a clinicial trial protocol document"}, {"role": "user", "content": "[Title: A Phase 2a Randomized, Blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MEDI0382 in Overweight/Obese Subjects with Type 2 Diabetes Mellitus, Study Description: This is a randomized, blinded, placebo-controlled study designed to evaluate the safety, tolerability, PK, and efficacy of ascending doses of MEDI0382 in overweight or obese subjects with T2DM. Subjects will have a BMI ≥ 27 and ≤ 35 kg/m2, be aged 18-74 years, and on metformin monotherapy. The study includes a 10-day run-in, an 8-week up-titration, and a 3-week treatment extension period, Objectives: Assess the safety, tolerability, pharmacokinetics, immunogenicity, glucose control effects, and weight loss efficacy of MEDI0382 up to the highest clinically tolerated dose, Endpoints: Primary endpoints include incidence of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs), vital signs, clinical lab evaluations, and ECG changes. Secondary endpoints include PK profile characterization, ADA incidence, changes in fasting glucose, HbA1c, and body weight, Study Population: Overweight or obese subjects with T2DM aged 18-74 years, with a BMI between 27 and 35 kg/m2 and on metformin monotherapy, Phase: Phase 2a, Description of Sites/Facilities Enrolling Participants: Sites equipped for inpatient and outpatient assessments with capabilities for safety evaluations, PK/PD sampling, and ambulatory blood pressure monitoring, Description of Study Intervention: MEDI0382 administered via subcutaneous injection once daily in the morning, with dose titration to determine the highest clinically tolerated dose, Study Duration: The study includes a 10-day run-in, an 8-week up-titration, a 3-week treatment extension period, and a 28-day follow-up, Participant Duration: Participation includes approximately 18 weeks from screening to follow-up.]"}, {"role": "assistant", "content": "[[Primary Objectives: Assess the safety and tolerability of MEDI0382 titrated up to the highest clinically tolerated dose (HCTD), Corresponding Endpoints: Incidence of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs) through the end of the up-titration period (up to 8 weeks) and through the end of the follow-up period; Clinically important changes in 12-lead electrocardiogram (ECG), vital signs (including heart rate and blood pressure), physical examination, and clinical laboratory evaluations through the end of the up-titration period (up to 8 weeks) and through the end of the follow-up period],[Secondary Objectives: Characterize the PK profile of MEDI0382 titrated up to the HCTD; Characterize the immunogenicity of MEDI0382 titrated up to the HCTD; Assess the effects of MEDI0382, titrated up to the HCTD, on additional measures of glucose control; Assess the effects of MEDI0382, titrated up to the HCTD, on body weight, Corresponding Endpoints: PK endpoints include area under the concentration-time curve (AUC) over a dosing duration (AUCtau), maximum observed concentration (Cmax), time to Cmax (Tmax), trough plasma concentration (Ctrough), and accumulation ratio (Cmin [R0]); Immunogenicity measured via anti-drug antibodies (ADAs) to MEDI0382 at baseline through the end of study; Glucose control endpoints include changes in fasting plasma glucose from Day -1 versus each week of the up-titration period, the end of the up-titration period, and the end of the treatment extension period; changes in HbA1c from Day -1 to the end of the treatment extension period; Body weight endpoints include percentage and absolute changes in body weight from baseline to the end of the up-titration period and the end of the treatment extension period; proportion of subjects achieving > 5% body weight loss from baseline to the end of the treatment extension period],[Tertiary/Exploratory Objectives: Not explicitly listed in this document, Corresponding Endpoints: Not explicitly listed in this document]]"}]}
{"messages": [{"role": "system", "content": "You are a clinical protocol document generator, given a synopsis you are tasked to construct the objectives and endpoints section for a clinicial trial protocol document"}, {"role": "user", "content": "[Title: A Phase 2, Parallel, Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Insulin-Naïve Patients with Type 2 Diabetes Mellitus, Study Description: This study evaluates LY3209590 in insulin-naïve patients with type 2 diabetes mellitus (T2DM), compared with insulin degludec. The study duration is set at 26 weeks to ensure adequate exposure and assess glycemic control, hypoglycemia, and weight gain. Insulin degludec is an unblinded active comparator., Objectives: Primary Objective: To investigate the efficacy of LY3209590 compared with insulin degludec in study participants with T2DM. Secondary Objective: To evaluate fasting glucose changes, safety (e.g., hypoglycemia events), and characterize the pharmacokinetics of LY3209590., Endpoints: HbA1c change from baseline to Week 26 (primary). Secondary endpoints include HbA1c change to Week 12, fasting glucose change, and hypoglycemia event rates., Study Population: Insulin-naïve patients with type 2 diabetes mellitus (T2DM), treated with a stable dose of metformin, alone or in combination with a stable dose of a DPPIV inhibitor and/or an SGLT2 inhibitor, for at least 3 months prior to screening., Phase: Phase 2, Description of Sites/Facilities Enrolling Participants: Multicenter study sites equipped for diabetes management and drug administration., Description of Study Intervention: LY3209590 is administered subcutaneously weekly per Algorithm 1 (Paper Algorithm). Insulin degludec is administered daily, dosed using a modified Riddle algorithm., Study Duration: Approximately 33 weeks (2-week screening, 26-week treatment, 5-week safety follow-up)., Participant Duration: Up to 33 weeks.]"}, {"role": "assistant", "content": "[[Primary Objectives: To investigate the efficacy of LY3209590 compared with insulin degludec in study participants with T2DM, Corresponding Endpoints: HbA1c change from baseline to Week 26]],[[Secondary Objectives: To investigate the efficacy, safety, and pharmacokinetics of LY3209590 compared with insulin degludec in study participants with T2DM, Corresponding Endpoints: Efficacy - HbA1c change from baseline to Week 12, Fasting glucose change from baseline to Weeks 12 and 26. Safety - Incidence and rate of hypoglycemia events during the treatment period, Incidence of treatment-emergent serious adverse events. Pharmacokinetics - Steady state AUC at Week 26]],[[Tertiary/Exploratory Objectives: To establish the equivalent dose of LY3209590 relative to insulin degludec, To investigate the safety and tolerability of LY3209590 compared with insulin degludec in study participants with T2DM, To establish the relationships between dose/exposure and key safety and efficacy measures for LY3209590, To characterize the effects of LY3209590 on exploratory PD biomarkers, To characterize Continuous Glucose Monitoring Parameters derived from FGM, To explore the development of LY3209590 ADAs, To explore the compliance with the dosing regimen, Corresponding Endpoints: Insulin dose at baseline and Week 26, Treatment-emergent adverse events, Incidence and rate of hypoglycemia events during the post-treatment follow-up period, Discontinuation of IP due to adverse events, Clinical laboratory results, Injection site reactions, Liver aminotransferase change from baseline to Weeks 12 and 26, Triglyceride and FFA change from baseline to Weeks 12 and 26, Body weight change from baseline at Weeks 12 and 26, LY3209590 exposure-response relationships for key efficacy and safety measures, Lipids (cholesterol, LDL, HDL, triglycerides), Biomarkers of lipolysis (FFA), SMBG glucose profiles, Various parameters derived from FGM, The frequency of antibody formation to LY3209590 and relationship to safety and efficacy markers, Incidence and percentage of missed doses of LY3209590 and insulin degludec]]​"}]}
{"messages": [{"role": "system", "content": "You are a clinical protocol document generator, given a synopsis you are tasked to construct the objectives and endpoints section for a clinicial trial protocol document"}, {"role": "user", "content": "[Title: A Phase 2a, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3-Way Crossover Study to Compare Safety, Efficacy, and Pharmacodynamics of Single and Multiple Doses of ORMD-0801 or Placebo in Adult Subjects with Type 2 Diabetes Mellitus, Study Description: This study is a 3-way crossover clinical trial involving ORMD-0801 or placebo aimed at comparing safety, efficacy, and pharmacodynamics for adult subjects with Type 2 Diabetes Mellitus. It includes single and multiple doses with pre-treatment, treatment, and washout periods, conducted with approximately 30 participants aged 20-75, Objectives: Primary objectives include comparing pre-treatment to end-of-treatment 24-hour CGM glucose levels and evaluating safety parameters. Secondary objectives include comparing daytime and nighttime CGM glucose, post-prandial glucose, insulin PK, C-peptide PD, and hypoglycemic events, Endpoints: Endpoints encompass glucose monitoring, insulin pharmacokinetics, C-peptide pharmacodynamics, and events of hypoglycemia. Data will be analyzed for safety and efficacy using CGM, Participant Duration: Subjects will be evaluated for eligibility during a 7-10 day screening period and participate for approximately 65 days, including treatment and follow-up phases.]"}, {"role": "assistant", "content": "[[Primary Objectives: To compare pre-treatment (Day 3) to end of treatment (Day 8) 24-hour CGM glucose for single and multiple doses of ORMD-0801 vs placebo. To evaluate safety parameters for single and multiple doses of ORMD-0801 vs placebo., Corresponding Endpoints: The primary endpoints include changes in 24-hour CGM glucose levels and evaluation of safety through clinical assessments and adverse event tracking.]], [[Secondary Objectives: To compare pre-treatment (Day 3) to end of treatment (Day 8) mean daytime CGM glucose for single and multiple doses of ORMD-0801 vs placebo. To compare pre-treatment (Day 3) to end of treatment (Day 8) mean nighttime CGM glucose for single and multiple doses of ORMD-0801 vs placebo. To compare pre-treatment (Day 3) to post-treatment washout (Day 9) 24-hour CGM glucose for single and multiple doses of ORMD-0801 vs placebo. To compare post-prandial glucose measurements for single and multiple doses of ORMD-0801 vs placebo., Corresponding Endpoints: Secondary endpoints involve measures such as daytime and nighttime CGM glucose changes, post-prandial glucose, and responses during post-treatment washout periods.]], [[Tertiary/Exploratory Objectives: Not explicitly mentioned in the document, Corresponding Endpoints: Not explicitly mentioned in the document.]]"}]}
{"messages": [{"role": "system", "content": "You are a clinical protocol document generator, given a synopsis you are tasked to construct the objectives and endpoints section for a clinicial trial protocol document"}, {"role": "user", "content": "[Title: A Randomized, Double Blind, Phase 2b Study to Evaluate the Effect of ORMD-0801 Compared to Placebo on Endogenous Glucose Production in Patients with Type 2 Diabetes Mellitus, Study Description: This study is designed to explore the efficacy of ORMD-0801 compared to placebo on endogenous glucose production in subjects with type 2 diabetes (T2DM). Subjects will undergo an initial Screening Visit (Visit 0) to establish their eligibility to participate in the study. At Visit 1 (2 weeks after the Screening Visit), qualifying subjects will be randomized to either ORMD-0801 (8 mg) or matching placebo, study medication will be dispensed and subjects will dose twice a day, once in the morning prior to breakfast and once at night prior to bedtime., Objectives: Primary Objective: To assess the differences in endogenous glucose production in subjects with type 2 diabetes treated for 4 weeks either with ORMD-0801 or matching placebo following an intravenous infusion of [6,6-2H2]-glucose tracer using AUC(0-last). Secondary Objectives: To compare changes in baseline levels of HbA1c, plasma glucose, ketones, FFAs, and lipid profiles in subjects treated with ORMD-0801 or placebo., Endpoints: Primary Endpoint: Difference in endogenous glucose production between active and placebo as measured by glucose with tracer attached using AUC(0-16). Secondary Endpoints: Changes in HbA1c, plasma glucose, ketones, FFAs, and lipid profiles from baseline., Study Population: Approximately 40 adult male and female subjects, aged 18 to 70 years, with T2DM., Phase: Phase 2b, Description of Sites/Facilities Enrolling Participants: Principal Investigators: Joel M. Neutel, M.D. (Orange County Research Center) and Ele Ferrannini, M.D. (CNR Institute of Clinical Physiology, Pisa, Italy)., Description of Study Intervention: ORMD-0801 (8 mg insulin) administered twice daily in soft gel capsules compared to placebo., Study Duration: 4 weeks, Participant Duration: 4 weeks plus a 1 to 3-week screening period.]"}, {"role": "assistant", "content": "Primary Objectives: To assess the differences in endogenous glucose production in subjects with type 2 diabetes treated for 4 weeks either with ORMD-0801 or matching placebo following an intravenous infusion of [6,6-2H2]-glucose tracer using AUC(0-last). Corresponding Endpoints: Difference in endogenous glucose production between active and placebo as measured by the glucose with tracer attached using AUC(0-16) as the primary parameter. Secondary Objectives: To compare the change from baseline in HbA1c levels measured at Week 4 in type 2 diabetic patients treated for 4 weeks with either ORMD-0801 or matching placebo. To compare the change from baseline in plasma glucose levels measured at Week 4 in type 2 diabetic patients treated for 4 weeks with either ORMD-0801 or matching placebo. To compare the change from baseline in ketone levels measured at Week 4 in type 2 diabetics treated for 4 weeks with either ORMD-0801 or matching placebo. To compare the change from baseline in FFAs measured at Week 4 in type 2 diabetics treated for 4 weeks with either ORMD-0801 or matching placebo. To compare the change from baseline in TC, LDLC, HDLC, and TG measured at Week 4 in type 2 diabetics treated for 4 weeks with either ORMD-0801 or matching placebo. To assess the differences in endogenous glucose production in patients with type 2 diabetes treated for 4 weeks either with ORMD-0801 or matching placebo following an intravenous infusion of [6,6-2H2]-glucose tracer using other parameters including, but not limited to, Cmax, Tmax, Tlag, and AUC over different time intervals. To assess the safety of repeat administration of ORMD-0801 in patients with type 2 diabetes inadequately controlled on oral therapy. Corresponding Endpoints: Mean changes in HbA1c from baseline to Day 29 of the treatment period. Mean changes in plasma glucose levels from baseline to Day 29 of the treatment period. Mean changes in ketones from baseline to Day 29 of the treatment period. Mean Changes in FFA from baseline to Day 29 of the treatment period. Mean change in TC, LDLC, HDLC, and TG from baseline to Day 29 of the treatment period. 6a. Difference in endogenous glucose production between active and placebo as measured by the glucose with tracer attached using other parameters including, but not limited to: AUC(0-2), AUC(0-4), AUC(0-8), AUC(0-12), AUC(2-16), AUC(4-16), AUC(8-16), AUC(12-16), Cmax, Tmax, and Tlag. 6b. Difference in metabolites (β-hydroxybutyrate, acetoacetate, lactate, pyruvate, FFA, glycerol) and hormones (insulin, C-peptide, glucagon) between active and placebo using the same AUC intervals as endogenous glucose production. Safety assessed by adverse event reporting including adverse events of special significance such as hypoglycemia. Tertiary/Exploratory Objectives:"}]}
{"messages": [{"role": "system", "content": "You are a clinical protocol document generator, given a synopsis you are tasked to construct the objectives and endpoints section for a clinicial trial protocol document"}, {"role": "user", "content": "[Title: A Phase 2 Study of Once-Weekly LY3298176 Compared with Placebo and Dulaglutide in Patients with Type 2 Diabetes Mellitus,Study Description: Study I8F-MC-GPGB is a 26-week Phase 2 study designed to examine the safety, efficacy, and pharmacokinetics (PK)/pharmacodynamics (PD) of 4 dose levels of once-weekly (QW) LY3298176 compared with QW dulaglutide 1.5 mg and QW placebo in patients with type 2 diabetes mellitus (T2DM) who have inadequate glycemic control with diet and exercise with or without a stable dose of metformin.Objectives: The primary objective is to demonstrate a dose-response relationship of QW subcutaneous injections of LY3298176 on HbA1c change from baseline relative to placebo. Secondary objectives include determining the effect of LY3298176 versus dulaglutide and placebo on body weight changes, HbA1c levels, fasting glucose, lipid profiles, and safety markers.Endpoints: Primary endpoint is the change in HbA1c from baseline to 26 weeks. Secondary endpoints include changes in mean body weight, fasting blood glucose, lipid levels, and percentages of patients achieving specific HbA1c targets or weight loss thresholds.Study Population: Patients aged 18 to 75 years with T2DM inadequately controlled with diet and exercise or metformin (≥1000 mg/day) with a BMI between 23 and 50 kg/m².Phase: Phase 2Description of Sites/Facilities Enrolling Participants: Multicenter, multi-country study. Specific site descriptions are not detailed but involve facilities capable of handling the requirements of a randomized, controlled clinical trial for T2DM. Description of Study Intervention: 4 parallel dose groups of LY3298176 (1 mg, 5 mg, 10 mg, 15 mg QW) compared with dulaglutide 1.5 mg and placebo administered via subcutaneous injections for 26 weeks. Dose titration is included for higher LY3298176 doses. Study Duration: 26 weeks of treatment with a follow-up safety visit approximately 4 weeks after the last dose. Participant Duration: Approximately 30 weeks, including screening and follow-up phases.**]"}, {"role": "assistant", "content": "[[Primary Objectives: To demonstrate a dose–response relationship of once-weekly subcutaneous injections of LY3298176 on HbA1c change from baseline relative to placebo in patients with T2DM inadequately contrlled with diet and exercise alone or treated with a stable dose of metformin. Corresponding Endpoints: The change in HbA1c from baseline to 26 weeks], [Secondary Objectives: To determine the effect of LY3298176 versus dulaglutide and placebo on multiple metrics including body weight change, HbA1c levels, fasting glucose, lipid profiles, and the proportion of patients achieving specific weight loss and glycemic targets. Additionally, assess safety and tolerability, the development of treatment-emergent antibodies, pharmacokinetics (PK), and pharmacodynamics (PD). Corresponding Endpoints: Body weight change, HbA1c levels at 12 and 26 weeks, fasting blood glucose changes, lipid profiles, waist circumference, incidence of hypoglycemia, anti-LY3298176 antibodies, PK and PD metrics, and dose-response analyses], [Tertiary/Exploratory Objectives: To evaluate biomarkers, genetic factors affecting LY3298176 efficacy and safety, patient-reported outcomes (PRO), and additional exploratory analyses on efficacy and safety parameters. Corresponding Endpoints: Biomarker changes, genetic variant analyses related to glucagon signaling and other pathways, changes in PRO measures, and exploratory efficacy and safety profiles at multiple time points]​"}]}
{"messages": [{"role": "system", "content": "You are a clinical protocol document generator, given a synopsis you are tasked to construct the objectives and endpoints section for a clinicial trial protocol document"}, {"role": "user", "content": "[Title: A Phase 2, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants with Type 2 Diabetes Mellitus Previously Treated with Basal Insulin, Study Description: Study I8H-MC-BDCM (BDCM) is a multicenter, randomized, open-label, comparator-controlled Phase 2 study with 3 study periods: 2-week screening, 32-week treatment period, and 5-week safety follow-up period. The study is designed to evaluate the efficacy and safety of LY3209590 compared to insulin degludec in study participants with T2DM. The primary endpoint will be hemoglobin A1c (HbA1c) change from baseline to 32 weeks, Objectives: Primary - To investigate the efficacy of LY3209590 arms in study participants with T2DM. Secondary - Efficacy, Safety, and Pharmacokinetics: to investigate the efficacy and safety of LY3209590 compared with insulin degludec in study participants with T2DM. Exploratory objectives include evaluating dose-response relationships and tolerability, Endpoints: HbA1c change from baseline to Week 32 for the LY3209590 arms (primary). Secondary endpoints include HbA1c change from baseline to Week 12, fasting glucose change, insulin dose change, and safety events, Study Population: Approximately 536 participants with T2DM previously treated with basal insulin will be screened. About 375 participants will be randomized to treatment groups, Phase: Phase 2, Description of Sites/Facilities Enrolling Participants: Multicenter study sites. Specific facilities were not detailed in the extracted content, Description of Study Intervention: LY3209590 administered weekly via subcutaneous injection in two dosing algorithms; insulin degludec administered daily, Study Duration: Approximately 39 weeks (2-week screening, 32-week treatment, and 5-week safety follow-up), Participant Duration: Total of approximately 39 weeks per participant.]"}, {"role": "assistant", "content": "[[Primary Objectives: To demonstrate a dose–response relationship of once-weekly subcutaneous injections of LY3298176 on HbA1c change from baseline relative to placebo in patients with T2DM inadequately controlled with diet and exercise alone or treated with a stable dose of metformin.Corresponding Endpoints: The change in HbA1c from baseline to 26 weeks][Secondary Objectives: To determine the effect of LY3298176 versus dulaglutide and placebo on multiple metrics including body weight change, HbA1c levels, fasting glucose, lipid profiles, and the proportion of patients achieving specific weight loss and glycemic targets. Additionally, assess safety and tolerability, the development of treatment-emergent antibodies, pharmacokinetics (PK), and pharmacodynamics (PD).Corresponding Endpoints: Body weight change, HbA1c levels at 12 and 26 weeks, fasting blood glucose changes, lipid profiles, waist circumference, incidence of hypoglycemia, anti-LY3298176 antibodies, PK and PD metrics, and dose-response analyses],[Tertiary/Exploratory Objectives: To evaluate biomarkers, genetic factors affecting LY3298176 efficacy and safety, patient-reported outcomes (PRO), and additional exploratory analyses on efficacy and safety parameters.Corresponding Endpoints: Biomarker changes, genetic variant analyses related to glucagon signaling and other pathways, changes in PRO measures, and exploratory efficacy and safety profiles at multiple time points]​"}]}
{"messages": [{"role": "system", "content": "You are a clinical protocol document generator, given a synopsis you are tasked to construct the objectives and endpoints section for a clinicial trial protocol document"}, {"role": "user", "content": "[Title: A Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of Multiple Doses of REMD-477 in Subjects with Type 1 Diabetes Mellitus, Study Description: A randomized, placebo-controlled, double-blind study conducted to evaluate the efficacy, safety, and pharmacodynamics of multiple doses of REMD-477 in subjects with Type 1 Diabetes Mellitus receiving insulin treatment. It aims to determine if glucagon receptor blockade with REMD-477 can decrease daily insulin requirements and improve glycemic control, Objectives: The primary objective is to compare the effects of multiple doses of REMD-477 versus placebo on changes from baseline at Week 12 in daily insulin requirements. Secondary objectives include comparing glycemic control, safety, tolerability, hypoglycemic episodes, and changes in HbA1C, among others. Exploratory objectives involve effects on body weight, quality of life scores, and intrahepatic lipid content., Endpoints: Primary endpoint is the change from baseline at Week 12 in daily insulin use. Secondary endpoints include changes in fasting glucose, glucose AUC, HbA1c, and C-peptide AUC. Exploratory endpoints involve body weight and intrahepatic lipid content, Study Population: Approximately 150 subjects aged 18-65 years with Type 1 Diabetes Mellitus, diagnosed as per ADA criteria, and meeting specific inclusion and exclusion criteria, Phase: Phase 2, Description of Sites/Facilities Enrolling Participants: Conducted at multiple sites across the United States, involving clinical research units equipped to perform intensive diabetes-related assessments, Description of Study Intervention: REMD-477 is a fully human IgG2 monoclonal antibody that binds to the human glucagon receptor, administered via subcutaneous injections at doses of 35 mg or 70 mg. Placebo is similarly administered, Study Duration: Total study duration is approximately 24 weeks per participant, including screening, lead-in, dosing, and follow-up periods, Participant Duration: Participants are enrolled for up to 24 weeks, including a screening period, 12 weeks of treatment, and 12 weeks of follow-up.]"}, {"role": "assistant", "content": "[ [Primary Objectives: To investigate the efficacy of LY3209590 arms in study participants with T2DM, Corresponding Endpoints: HbA1c change from baseline to Week 32], [Secondary Objectives: Efficacy: To investigate the efficacy of LY3209590 compared with insulin degludec in study participants with T2DM. Safety: To investigate the safety of LY3209590 compared with insulin degludec in study participants with T2DM. Pharmacokinetics: To characterize the PK of LY3209590 in study participants with T2DM, Corresponding Endpoints: Efficacy Endpoints: HbA1c change from baseline to Week 12 and Week 32; fasting glucose change from baseline to Week 12 and Week 32; insulin dose change from baseline to Week 12 and Week 32. Safety Endpoints: Incidence and rate of hypoglycemia, nocturnal hypoglycemia, and severe hypoglycemia; incidence of treatment-emergent serious adverse events; body weight change from baseline at Week 12 and Week 32. Pharmacokinetics Endpoints: LY3209590 population-based parameters, such as AUC within dosing interval at Week 12 and Week 32], [Tertiary/Exploratory Objectives: To investigate the safety and tolerability of LY3209590 compared with insulin degludec in study participants with T2DM; To explore the quality of glycemic control using CGM; To establish the relationships between dose/exposure and key safety and efficacy measures for LY3209590, Corresponding Endpoints: Treatment-emergent adverse events; discontinuation of investigational product due to adverse events; systematic assessment of injection site reactions; glycemic measures like glucose time in target range, time in hypoglycemia, and time in hyperglycemia; plasma lipids and biomarkers of lipolysis (FFA); and LY3209590 exposure-response relationships]"}]}
{"messages": [{"role": "system", "content": "You are a clinical protocol document generator, given a synopsis you are tasked to construct the objectives and endpoints section for a clinicial trial protocol document"}, {"role": "user", "content": "[Title: A double-blind, randomized, placebo-controlled, multiple-dose, two-center, safety and efficacy study of co-administration of tesofensine/metoprolol treatment in subjects with type 2 diabetes mellitus (T2DM), Study Description: This study involves a randomized, double-blind, placebo-controlled, multiple-dose design across two centers. It evaluates the safety and efficacy of tesofensine and metoprolol co-administration compared to placebo in adults with T2DM., Objectives: Primary objective: To compare the effects of tesofensine/metoprolol co-administration versus placebo on 24-hour mean heart rate. Secondary objectives include comparing the effects on systolic/diastolic blood pressure, body weight, glycaemic endpoints, body composition (liver fat), and evaluating safety and tolerability., Endpoints: Primary: Change from baseline to the end of treatment in mean 24-hour heart rate. Secondary: Changes in systolic and diastolic blood pressure, body weight, HbA1c, fasting plasma glucose, and 9-point blood glucose profile. Other endpoints include changes in liver fat, fasting insulin, and 1,5-anhydroglucitol levels., Study Population: Adults aged 18–70 years with confirmed T2DM, normal or well-managed blood pressure and lipid profiles, stable metformin usage, and HbA1c ≥7.0%. Exclusion criteria include HbA1c >8.5%, significant cardiovascular history, and psychiatric conditions., Phase: Phase 2a, Description of Sites/Facilities Enrolling Participants: The study is conducted at two investigational sites in Germany., Description of Study Intervention: Two arms: (1) Tesofensine (0.5 mg) and Metoprolol (100 mg) administered daily with meals, starting with a loading dose of 1.0 mg for two days; (2) Placebo tablets matching tesofensine and Metoprolol., Study Duration: January 2016 – December 2016, with treatment lasting 90 days., Participant Duration: Approximately 138 days, including screening, baseline assessments, treatment, and final follow-up.]"}, {"role": "assistant", "content": "[[Primary Objectives: To compare the effects of multiple doses of REMD-477 versus placebo on change from baseline at Week 12 in daily insulin requirements, Corresponding Endpoints: Change from baseline at Week 12 in daily insulin use​],[Secondary Objectives: To compare the effects of multiple doses of REMD-477 versus placebo on measures of glycemic control including fasting glucose and glucose AUC, daily blood glucose concentration, HbA1C, pancreatic function, and the safety and tolerability of REMD-477, Corresponding Endpoints: Changes in fasting glucose, glucose AUC, HbA1C, insulin use ratio, and adverse event incidence​​],[Tertiary/Exploratory Objectives: To explore changes in body weight, quality of life score, and intrahepatic lipid content, Corresponding Endpoints: Changes in body weight, quality of life score, and intrahepatic lipid content as measured by MRI-PDFF and FibroScan®​ ]]"}]}
{"messages": [{"role": "system", "content": "You are a clinical protocol document generator, given a synopsis you are tasked to construct the objectives and endpoints section for a clinicial trial protocol document"}, {"role": "user", "content": "[Title: A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MEDI0382 in Overweight and Obese Subjects with a History of Type 2 Diabetes Mellitus, Study Description: This study involves evaluating MEDI0382 in overweight and obese subjects with type 2 diabetes mellitus (T2DM). It aims to assess efficacy, safety, and pharmacokinetics, focusing on glucose control and weight reduction., Objectives: Primary Objective: To assess the effect of MEDI0382 on glucose control and body weight over a 4-week treatment period. Secondary Objectives: To evaluate glucose control, safety, pharmacokinetics, and pharmacodynamics. Exploratory Objectives: To examine effects on liver fat and body composition., Endpoints: Primary Endpoints include percent change in glucose AUC and body weight. Secondary Endpoints cover HbA1c changes, adverse events, and various safety parameters., Study Population: The study includes adults aged 18-65 with T2DM and BMI 27-40 kg/m², on stable blood glucose-lowering therapy., Phase: Phase 1/2., Description of Sites/Facilities Enrolling Participants: Approximately 12 study sites with infrastructure for handling clinical trials., Description of Study Intervention: MEDI0382 or placebo, administered subcutaneously daily, with doses adjusted based on safety and efficacy., Study Duration: Varies by cohort, with a maximum of 48 days for the longest cohort., Participant Duration: Includes screening, inpatient, and outpatient periods, totaling up to approximately 76 days for some participants.]"}, {"role": "assistant", "content": "[[Primary Objectives: Evaluate the pharmacodynamic (PD) properties of a single dose of PRAM9 compared to single doses of regular insulin and regular insulin plus pramlintide (co-administered as separate injections) in adults with T1D., Corresponding Endpoints: Area under the curve (AUC0-180) (mg/dL × minutes) for plasma glucose > 180 mg/dL], [Secondary Objectives: Evaluate the safety and pharmacokinetic (PK) profiles of a single dose of PRAM9 compared to single doses of regular insulin and regular insulin plus pramlintide (co-administered as separate injections) in adults with T1D., Corresponding Endpoints: Safety endpoints include incidence of adverse events (AEs) and serious adverse events (SAEs), changes from baseline in vital signs and laboratory safety variables, changes in body weight, local tolerability assessments; Pharmacokinetic and pharmacodynamic endpoints include PK plasma levels (AUC0-90 min, AUC0-180 min, AUC0-360 min, Cmax, and Tmax) for both insulin and pramlintide], [Tertiary/Exploratory Objectives: Not specified in the document, Corresponding Endpoints: Not specified in the document]]."}]}
{"messages": [{"role": "system", "content": "You are a clinical protocol document generator, given a synopsis you are tasked to construct the objectives and endpoints section for a clinicial trial protocol document"}, {"role": "user", "content": "[Title: A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Different Doses of MEDI0382 in Overweight and Obese Subjects with Type 2 Diabetes Mellitus, Study Description: To assess the effects of MEDI0382 titrated up to a dose level of 300 μg on glucose control and body weight versus placebo after 49 days of treatment, Objectives: To assess the effects of MEDI0382 on glucose control and weight loss and characterize its safety and pharmacokinetic profiles, Endpoints: Percentage change in glucose AUC as measured by a mixed-meal tolerance test (MMTT) and body weight from baseline after 49 days, Study Population: Overweight and obese subjects with type 2 diabetes mellitus (T2DM) aged ≥ 18 years with a BMI between 27 and 40 kg/m2 and stable HbA1c levels managed with metformin, Phase: Phase 2, Description of Sites/Facilities Enrolling Participants: Multiple clinical sites, Description of Study Intervention: MEDI0382 or placebo administered via subcutaneous injection with dose escalation from 50 μg to 300 μg, Study Duration: 49 days of treatment with follow-up visits, Participant Duration: Approximately 77 days including screening, treatment, and follow-up.]"}, {"role": "assistant", "content": ""}]}
